Form 4: Atea Pharmaceuticals Director Bruno Lucidi Reports Stock Transaction
SEC Form 4 Filing
Director Bruno Lucidi reports the conversion of restricted stock units into common stock of Atea Pharmaceuticals.
Summary
- On June 16, 2024, Bruno Lucidi, a director of Atea Pharmaceuticals, Inc., converted 33,150 restricted stock units into common stock.
- The transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Lucidi beneficially owns 83,150 shares of Atea Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are closely watched by investors for signals about management's confidence in the company's future prospects.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the number of outstanding shares, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 06/16/2024 | Date of transaction: Conversion of restricted stock units to common stock. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.